Get the Stockscreener App
4.09
3.31%
-0.14
Cytek Biosciences Inc stock is traded at $4.09, with a volume of 334.45K.
It is down -3.31% in the last 24 hours and down -6.19% over the past month.
Cytek Biosciences Inc is a cell analysis solutions company advancing the next generation of research and clinical tools with its novel technical approach of leveraging the full spectrum of fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells. Its patented FSP technology optimizes sensitivity and accuracy through its optical and electronic designs that utilize an inventive method of light detection and distribution to a specifically selected number and type of detectors. Its FSP cell analyzers, the Cytek Aurora, Northern Lights, and Cytek Aurora Evo systems, deliver high-resolution, high-content and high-sensitivity cell analysis and address the inherent limitations of other technologies.
See More
Previous Close:
$4.23
Open:
$4.18
24h Volume:
334.45K
Relative Volume:
0.36
Market Cap:
$526.41M
Revenue:
$201.49M
Net Income/Loss:
$-66.54M
P/E Ratio:
-7.8699
EPS:
-0.5197
Net Cash Flow:
$-8.88M
1W Performance:
-7.26%
1M Performance:
-6.19%
6M Performance:
-0.97%
1Y Performance:
-4.44%
1-Day Range:
$4.08
$4.2068
1-Week Range:
$4.08
$4.485
52-Week Range:
$2.37
$6.18
Cytek Biosciences Inc Stock (CTKB) Company Profile
Name
Cytek Biosciences Inc
Sector
Industry
Phone
(877) 922-9835
Address
47215 LAKEVIEW BOULEVARD, FREMONT
Compare CTKB vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CTKB
Cytek Biosciences Inc
|
4.095 | 543.77M | 201.49M | -66.54M | -8.88M | -0.5197 |
|
ABT
Abbott Laboratories
|
110.17 | 192.10B | 44.33B | 6.50B | 7.40B | 3.717 |
|
SYK
Stryker Corp
|
343.81 | 137.25B | 25.12B | 3.25B | 4.28B | 8.3984 |
|
MDT
Medtronic Plc
|
88.94 | 115.41B | 35.48B | 4.64B | 5.41B | 3.582 |
|
BSX
Boston Scientific Corp
|
68.82 | 103.81B | 20.08B | 2.89B | 3.66B | 1.9391 |
|
EW
Edwards Lifesciences Corp
|
84.61 | 49.82B | 6.07B | 1.06B | 1.34B | 1.8063 |
Cytek Biosciences Inc Stock (CTKB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-02-25 | Resumed | Morgan Stanley | Equal-Weight |
| May-09-25 | Downgrade | TD Cowen | Buy → Hold |
| Jan-31-25 | Downgrade | Goldman | Buy → Sell |
| Dec-14-23 | Initiated | Stephens | Overweight |
| Jul-19-23 | Initiated | Raymond James | Mkt Perform |
| Jan-06-22 | Resumed | Piper Sandler | Overweight |
View All
Cytek Biosciences Inc Stock (CTKB) Latest News
Cytek Biosciences expands global reach with one year of Singapore operations - Traders Union
Cytek Biosciences Celebrates One Year of Operations at Singapore Facility, Accelerating Growth and Regional Impact - Bitget
Cytek® Biosciences Celebrates One Year of Operations at Singapore Facility, Accelerating Growth and Regional Impact - Weekly Voice
Cytek Biosciences Highlights Aurora Evo, Recurring Revenue Growth and 2026 Outlook at TD Cowen Conference - Yahoo Finance
How The Cytek Biosciences (CTKB) Story Is Shifting With New Targets And 2026 Guidance - Yahoo Finance
Cytek Biosciences Balances Growth With Margin Strain - TipRanks
Royce & Associates LP Increases Holdings in Cytek Biosciences, Inc. $CTKB - MarketBeat
Cytek Biosciences, Inc. (NASDAQ:CTKB) Receives $5.50 Average PT from Brokerages - Defense World
CTKB SEC FilingsCytek Biosciences, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Cytek Biosciences at TD Cowen Health Care: Strategic Growth Insights By Investing.com - Investing.com Canada
Buyback Watch: What is the Moat Score of Cytek Biosciences IncStop Loss & AI Powered Buy and Sell Recommendations - baoquankhu1.vn
CTKB Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Cytek Biosciences outlines cell sorting breakthroughs in webinar - Traders Union
Cytek Biosciences, Inc. (NASDAQ:CTKB) Given Consensus Rating of "Hold" by Brokerages - MarketBeat
Cytek Biosciences, Inc. (NASDAQ:CTKB) Q4 2025 Earnings Call Transcript - Insider Monkey
Cytek Biosciences (NASDAQ:CTKB) Announces Quarterly Earnings Results, Misses Estimates By $0.36 EPS - MarketBeat
Earnings call transcript: Cytek Biosciences Q4 2025 sees record revenue, EPS miss - Investing.com South Africa
Cytek (CTKB) Q4 2025 Earnings Call Transcript - The Globe and Mail
Cytek Biosciences, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Cytek Biosciences, Inc. 2025 Q4ResultsEarnings Call Presentation (NASDAQ:CTKB) 2026-02-27 - Seeking Alpha
Cytek Biosciences (CTKB) Q4 EPS Swing To Loss Reinforces Margin Concerns - Sahm
Cytek Biosciences earnings missed by $0.32, revenue topped estimates - Investing.com Canada
Cytek Biosciences Q4 Earnings Call Highlights - Yahoo Finance
Earnings Call Summary | Cytek Biosciences(CTKB.US) Q4 2025 Earnings Conference - 富途牛牛
Cytek Biosciences, Inc. (CTKB) Reports Q4 Loss, Tops Revenue Estimates - Nasdaq
Cytek Biosciences Inc (NASDAQ:CTKB) Reports Q4 2025 Revenue Beat and Mixed Earnings - ChartMill
Cytek Biosciences Inc. (CTKB) Stock Falls on Q4 2025 Earnings - Quiver Quantitative
Cytek Biosciences (CTKB) swings to deeper 2025 loss with soft 2026 growth outlook - Stock Titan
Cytek Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results - Quiver Quantitative
Cytek Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Outlook - Yahoo Finance
Cytek Biosciences, Inc. (CTKB) Stock Analysis: Exploring a Potential 37% Upside Amid Challenging Valuations - DirectorsTalk Interviews
Aug Chart Watch: Is Cytek Biosciences Inc stock overvalued or fairly priced2025 Pullback Review & Low Drawdown Momentum Trade Ideas - baoquankhu1.vn
[Form 4] Cytek Biosciences, Inc. Insider Trading Activity - Stock Titan
Cytek Biosciences (CTKB) Expected to Announce Earnings on Thursday - Defense World
Cytek Biosciences to participate at the TD Cowen 46th Annual Health Care Conference - The Manila Times
Live March 4 Cytek Biosciences talk at TD Cowen health care conference - Stock Titan
CTKB Should I Buy - Intellectia AI
Cytek Biosciences, Inc.'s (NASDAQ:CTKB) Share Price Is Still Matching Investor Opinion Despite 27% Slump - simplywall.st
Cytek Biosciences to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026 - The Manila Times
Cytek Biosciences, Inc. (CTKB): Investor Outlook On A Promising 37.61% Upside Potential - DirectorsTalk Interviews
Is Cytek Biosciences Inc. in a long term uptrendJuly 2025 Weekly Recap & Long Hold Capital Preservation Plans - mfd.ru
Cytek Biosciences Stock (CTKB) Opinions on Preliminary Q4 and FY2025 Revenue Results - Quiver Quantitative
What are Cytek Biosciences Inc.’s technical support levels2025 Investor Takeaways & Expert Curated Trade Setup Alerts - mfd.ru
Can Cytek Biosciences Inc. stock hit analyst price targets2025 Market WrapUp & Real-Time Buy Signal Alerts - mfd.ru
New York State Common Retirement Fund Has $1.15 Million Holdings in Cytek Biosciences, Inc. $CTKB - MarketBeat
Why Cytek Biosciences Inc. stock is trending among retail tradersPortfolio Update Summary & AI Enhanced Market Trend Forecasts - mfd.ru
What You Can Learn From Cytek Biosciences, Inc.'s (NASDAQ:CTKB) P/S - 富途牛牛
Cytek Biosciences, Inc. (NASDAQ:CTKB) Given Consensus Rating of "Hold" by Analysts - MarketBeat
Brown Capital Management LLC Has $17.20 Million Position in Cytek Biosciences, Inc. $CTKB - MarketBeat
Cytek Biosciences (NASDAQ:CTKB) Trading Up 3.2% – Should You Buy? - Defense World
Cytek Biosciences (NASDAQ:CTKB) Trading Up 3.2%Should You Buy? - MarketBeat
Cytek Biosciences Inc Stock (CTKB) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.61%
1.47%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):